Picture of Dongwha Pharm Co logo

000020 Dongwha Pharm Co Share Price

0.000.00%
kr flag iconLast trade - 00:00
HealthcareAdventurousSmall CapSuper Stock

Momentum

Relative Strength (%)
1m-6.79%
3m-5.33%
6m-11.04%
1yr+9.35%
Volume Change (%)
10d/3m-47.38%
Price vs... (%)
52w High-14.48%
50d MA-2.9%
200d MA-4.23%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)7.16
PEG Ratio (f)0.37
EPS Growth (f)23.68%
Dividend Yield (f)1.89%
Valuation (ttm)IndustryMarket
Price to Book Value0.71
Price to Tang. Book0.84
Price to Free Cashflow93.44
Price to Sales0.73
EV to EBITDA8.09

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital3.98%
Return on Equity7.45%
Operating Margin5.06%

Financial Summary

Year End 31st DecUnit201920202021202220232024E2025ECAGR / Avg
Total RevenueKR₩m307,150.03272,075.38293,018.11340,426.33361,108.56407,300437,0003.33%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%-46.51+308.21-19.29+30.61+18.57+30.4+6.19n/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Dongwha Pharm Co EPS forecast chart

Profile Summary

DONGWHA PHARM.CO., LTD is a Korea-based company engaged in the manufacture of pharmaceuticals. The Company’s products consist of ethical drugs, including digestive system remedies, antibiotics, cardiovascular and metabolic disease treatments, non steroidal anti-inflammatory drugs, respiratory remedies, muscle relaxants, nervous system remedies, dermatological remedies and urinary system remedies, and over-the-counter (OTC) drugs, including cold remedies, dental remedies, dermatological remedies, hepatic protectors, nutrients, tonics, topical analgesics, anti-smoking agents and others. It also provides medicine raw materials, health food and drinks, as well as cosmetics. The Company distributes its products within domestic market and to overseas markets.

Directors

Last Annual
December 31st, 2023
Last Interim
December 31st, 2023
Incorporated
September 25th, 1897
Public Since
March 24th, 1976
No. of Shareholders
27,201
No. of Employees
723
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
kr flag iconKorea Exchange - KSE
Shares in Issue
27,717,930

000020 Share Price Performance

Upcoming Events for 000020

Similar to 000020

Picture of Aprogen Biologics logo

Aprogen Biologics

kr flag iconKorea Exchange - KSE

Picture of Boryung logo

Boryung

kr flag iconKorea Exchange - KSE

Picture of Bukwang Pharm Co logo

Bukwang Pharm Co

kr flag iconKorea Exchange - KSE

Picture of Chong Kun Dang Pharmaceutical logo

Chong Kun Dang Pharmaceutical

kr flag iconKorea Exchange - KSE

Picture of CKD Bio logo

CKD Bio

kr flag iconKorea Exchange - KSE

FAQ